Cancer Network Conferences

Article

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Barry Paul, MD, listed cilta-cel, anito-cel, and arlo-cel as 3 of the CAR T-cell therapies with the most promising efficacy in patients with multiple myeloma.
START is the largest early phase oncology network in the community-based setting, according to Geraldine O’Sullivan Coyne, MD, MRCPI, PhD.
Jose Sandoval Sus, MD, discussed standard CAR T-cell therapies in patients across multiple high-risk lymphoma indications.
Related Content
Shebli Atrash, MD, believes the future for treatment in multiple myeloma, as well as solid tumors and beyond, includes immune therapies.

Defining the Role of Immune Therapy in Multiple Myeloma

Roman Fabbricatore
August 9th 2025
Article
Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

Jacob Sands, MD
August 9th 2025
Podcast
Phase 2b findings demonstrate improved 2-year survival outcomes with OST-HER2 compared with historical control data.

OST-HER2 Yields Significant Survival in Pulmonary Metastatic Osteosarcoma

Russ Conroy
August 9th 2025
Article
Navigating Second-Line Treatment Options in Urothelial Carcinoma

Navigating Second-Line Treatment Options in Urothelial Carcinoma

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
August 9th 2025
Podcast
Zongertinib Earns FDA Accelerated Approval in HER2+ NSCLC

Zongertinib Earns FDA Accelerated Approval in HER2+ NSCLC

Russ Conroy
August 9th 2025
Article
Pre-planned interim results from the phase EPCORE FL-1 trial supported the FDA granting priority review to epcoritamab with rituximab and lenalidomide in relapsed/refractory FL.

SC Epcoritamab Combo Met ORR/PFS End Points in R/R Follicular Lymphoma

Tim Cortese
August 9th 2025
Article